Stephen B. Maebius

Stephen B. Maebius

Foley & Lardner LLP

Contact  |  View Bio  |  RSS

Latest Publications

Share:

Nanotech Drug Formulations Drive Dealmaking

Some of the most commercially successful products to arise out of nanotechnology in terms of sheer size of revenues generated are nanotech drug formulations. This area continues to be hot in the wake of two recent deals, both...more

5/15/2014 - Biotechnology Nanotechnology Pharmaceutical Prescription Drugs Technology

USPTO Issues New Guidelines on Subject Matter Eligibility Under 35 USC 101 in View of Myriad and Prometheus

The USPTO issued new guidelines for determining if claims are eligible for patenting in light of the Association for Molecular Pathology v. Myriad Genetics, Inc., 569 U.S., 133 S. Ct. 2107, 2116, 106 USPQ2d 1972 (2013), and...more

3/6/2014 - Patent-Eligible Subject Matter USPTO

Why Study the Draft 2014 National Nanotech Initiative Strategic Plan?

The NNI has just released its 2014 draft Strategic Plan for public comment. Aside from the opportunity to submit comments, becoming familiar with the plan offers a number of benefits to nanotech ventures. One is that it...more

12/9/2013 - Nanotechnology Technology

U.S. PTAB Issues First Final Decision in an Inter Partes Review

On November 13, 2013, the U.S. Patent Trial and Appeal Board (PTAB) issued its first final decision in an inter partes review (IPR) proceeding brought by Garmin under the new administrative procedures established by the...more

11/15/2013 - America Invents Act Inter Partes Review Proceedings Patent Reform Patent Trial and Appeal Board Patents

NanoBusiness Panel on Patents Featuring View From the US Patent Office

At a recent nanotech conference hosted by the NanoBusiness Commercialization Association, we received an update on nanotech patent trends from Jerry Lorengo, a Group Director with the US Patent Office. Jerry provided a great...more

11/13/2013 - Nanotechnology Patents Technology USPTO

Supreme Court Decides Myriad Case: Synthetic DNA Held Patentable & Implications for Nanotech

Today the Supreme Court rendered its decision in the landmark Myriad case, holding that naturally occurring DNA segments are not patentable, but synthetic DNA segments are patent eligible based on the patent eligibility...more

6/17/2013 - AMP v Myriad DNA Myriad Nanotechnology Patent-Eligible Subject Matter Patents SCOTUS

U.S. Patent Office Issues Guidance to Examiners on Supreme Court's Myriad Decision

Today the USPTO issued guidance (PTO_Myriad_Guidelines) to Examiners on how to apply the Myriad Supreme Court decision to applications under examination. The guidance states that claims drawn “solely to naturally occurring...more

6/17/2013

U.S. Patent "Micro-Entity" Rules & Other Cost Savings Strategies: Do You qualify for 75% Off Your U.S. Patent Filing Costs?

The short answer is that a company or individual who already is qualified as a small entity (which entitles you to 50% off U.S. patent filing costs) may also qualify under the final rules issued by the Patent Office for...more

6/14/2013 - Filing Fees Micro Entity Status Patent Applications Patents USPTO

Foley & Lardner LLP Launches Legal Innovation Hub for NextGen Manufacturers

Our firm recently launched its Legal Innovation HubSM for NextGen Manufacturers, a major firm-wide initiative to provide access to customized service for companies operating in this area. Nanotechnology is a major contributor...more

6/12/2013

2013 Lemelson-MIT Prize Awarded to Nanotech Scientist Angela Belcher

This year’s Lemelson-MIT Prize, which rewards inventors who improve the world through technological invention, has gone to pioneering nanotech scientist Angela Belcher. Dr. Belcher was inspired during her graduate work by the...more

6/11/2013 - Nanotechnology Scientific Research

Will the Supreme Court Limit Nanotech Patents?

In a case styled The Association for Molecular Pathology v. Myriad Genetics, the Supreme Court is confronting the question of whether or not human genes are patent eligible under 35 U.S.C. 101. A decision is expected in the...more

6/4/2013 - AMP v Myriad Biotechnology Gene Patenting Human Genes Infringement Myriad Nanotechnology Patents SCOTUS

Nanomedicine Hitting Its Stride? Beware of Patent Risks

Though the first nanoparticulate drug formulation was approved by the U.S. FDA way back in 1995, a recent flurry of deals and product approvals have shown increasingly high valuations for nanomedicine companies....more

6/4/2013 - FDA Nanomedicine Patents Pharmaceutical Safe Harbors

EU Moves Closer to a "Unitary" Patent Regime for Obtaining and Litigating Patents in Europe

On December 11, 2012, the European Parliament approved a set of three proposals to create (1) a “unitary” patent valid across 25 EU member states, (2) a simplified language regime for EU patents, and (3) a unified patent...more

12/13/2012 - EU Patents Unified Patent Court Unitary Patent

13 Results
|
View per page
Page: of 1